27-Hydroxycholesterol: a potential endogenous regulator of estrogen receptor signaling.

Trends in Pharmacological Sciences
Carolyn D DuSell, Donald P McDonnell

Abstract

The selective estrogen receptor modulators (SERMs) are synthetic pharmaceuticals, the relative agonist and antagonist activities of which are not equivalent in all cells. Their discovery has raised the possibility that endogenous small molecules might exist that have similar properties and could have important physiological roles. In support of this hypothesis is the recent demonstration that the oxysterol 27-hydroxycholesterol (27HC) interacts with and modulates the transcriptional activity of both estrogen receptor (ER) subtypes and that the relative agonist and antagonist activity of 27HC is influenced by both cell and promoter context. Although there is limited information available on the role of 27HC in classical estrogen-responsive tissues, that which is available in animal models of cardiovascular disease and cellular models of breast cancer support a role for this ligand in ER signaling. These results provide an interesting potential link between cholesterol (and cholesterol metabolism) and ER function, the physiological and pathological importance of which remains to be determined.

References

Mar 26, 1992·The New England Journal of Medicine·R R LoveD L DeMets
Jun 1, 1989·Clinical Rheumatology·A G Vagenakis
Jun 11, 1996·Proceedings of the National Academy of Sciences of the United States of America·G G KuiperJ A Gustafsson
Sep 1, 1997·Clinical Immunology and Immunopathology·D L JacobsonN M Graham
Nov 20, 1997·The Journal of Clinical Investigation·K S Christopherson, D S Bredt
Jan 27, 1999·Atherosclerosis·A J Brown, W Jessup
Apr 5, 2000·The Journal of Biological Chemistry·J Li-HawkinsD W Russell
Jun 17, 2000·Trends in Endocrinology and Metabolism : TEM·I Björkhem, E Leitersdorf
Jul 13, 2002·Annals of the New York Academy of Sciences·Luigi CastagnettaGiuseppe Carruba
Oct 10, 2002·Endocrine Reviews·Ken L Chambliss, Philip W Shaul
Feb 14, 2003·The New England Journal of Medicine·Francine GrodsteinJoAnn E Manson
Aug 13, 2003·Southern Medical Journal·Sally G Haskell
Feb 11, 2004·Endocrine Reviews·Carolyn L Smith, Bert W O'Malley
Sep 15, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A SverrisdóttirL E Rutqvist
Dec 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeremy J W ChenPan-Chyr Yang
Feb 8, 2005·Molecular Endocrinology·Linda Björnström, Maria Sjöberg
Jan 4, 2007·The Journal of Pathology·H S Chahal, W M Drake
May 25, 2007·Journal of Women's Health·Kristina A TheisJennifer M Hootman
May 29, 2007·International Review of Neurobiology·Robert N Schwendimann, Nadejda Alekseeva
Jun 20, 2007·International Journal of Clinical Practice·J F Simard, K H Costenbader
Jul 6, 2007·The Journal of Steroid Biochemistry and Molecular Biology·Shiuan ChenXiwei Wu
Sep 18, 2007·Molecular Endocrinology·Carolyn D DuSellDonald P McDonnell
Sep 18, 2007·Nature Medicine·Michihisa UmetaniDavid J Mangelsdorf
Sep 22, 2007·Journal of Cellular Physiology·Boris J CheskisLeonard P Freedman

❮ Previous
Next ❯

Citations

Aug 13, 2013·European Journal of Endocrinology·Sandra Pekic, Vera Popovic
Sep 26, 2013·Proceedings of the National Academy of Sciences of the United States of America·Toshi ShiodaKurt J Isselbacher
Oct 17, 2014·Climacteric : the Journal of the International Menopause Society·D P McDonnellE R Nelson
Feb 9, 2010·Trends in Pharmacological Sciences·Andrea CignarellaChiara Bolego
Mar 17, 2009·Best Practice & Research. Clinical Endocrinology & Metabolism·Vincenzo Di Marzo
Mar 28, 2013·Endocrine-related Cancer·Etienne Leygue, Leigh C Murphy
May 2, 2009·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·A Edward Friedman
May 1, 2010·Experimental and Therapeutic Medicine·Pamela CruzWalter Daniel Sierralta
Sep 29, 2020·British Journal of Pharmacology·Alzbeta Kloudova-SpalenkovaPavel Soucek
Jul 26, 2014·Cancer Research·Donald P McDonnellErik R Nelson
Feb 20, 2021·Frontiers in Oncology·Tiffany ScullyEmily Jane Gallagher
May 28, 2021·Biochemical Pharmacology·Liqian MaErik R Nelson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.

Autoimmune Polyendocrine Syndromes

This feed focuses on a rare genetic condition called Autoimmune Polyendocrine Syndromes, which are characterized by autoantibodies against multiple endocrine organs. This can lead to Type I Diabetes.

Cardiovascular Risk Reduction

Prevention of cardiovascular disease is an important health initiative. Risk reduction including physical activity, smoking cessation, diet, blood pressure lowering drugs and pharmacotherapy. Here is the latest research on cardiovascular risk reduction.